Name: Generating and Imaging Mouse and Human Epithelial Organoids from Normal and Tumor Mammary Tissue Without Passaging (Video) | JoVE Journal
Uploaded: 2022-11-11T14:30:00.000+00:00
Duration: 8 min 57 s
Description: Learn to generate epithelial organoids from normal and tumor mammary tissue without passaging using differential centrifugation. This method enables 3D culture and immunofluorescent imaging for cancer research.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

This study was supported by funding provided by METAvivor, the Peter Carlson Trust, Theresa&#39;s Research Foundation, and the NCI/UTSW Simmons Cancer Center P30 CA142543. We acknowledge the assistance of the University of Texas Southwestern Tissue Management Shared Resource, a shared resource at the Simmons Comprehensive Cancer Center, which is supported in part by the National Cancer Institute under award number P30 CA142543. Special thanks to all members of the Chan Lab.

All mouse tissue utilized in this manuscript has been ethically collected in accordance with the Institutional Animal Care and Use Committee (IACUC) regulations and guidelines of the University of Texas Southwestern Medical Center. Likewise, all the patients consented prior to tissue donation under the oversight of an Institutional Review Board (IRB), and the samples were deidentified.
NOTE: This protocol describes the generation of organoids from primary tissue.
1. Overnight preparation of materials
<ol>
	<li>For embedding in basement extracellular matrix (BECM), thaw the BECM aliquot by leaving it at 4 &#176;C.</li>
</ol>
2. Preparing collagenase and bovine serum albumin (BSA) coating solution
<ol>
	<li>Prepare 2.64% BSA/PBS coating solution (BSA Solution): Sterile filter 50 mL of phosphate-buffered saline (PBS) and 4.10 mL of 30% BSA solution using a 50 mL/0.2 &#181;m filter flask. This BSA solution can be filtered and used again.</li>
	<li>Prepare collagenase solution for mouse mammary tissue: Sterile filter 27 mL of basal cell medium, 1.5 mL of fetal bovine serum (FBS), 30 &#181;L of 50 mg/mL gentamicin, 15 &#181;L of 10 mg/mL insulin, 600 &#181;L of 0.1 g/mL collagenase A, and 600 &#181;L of 0.1 g/mL trypsin using a 50 mL/0.2 &#181;m filter flask. Allocate between 10 mL and 30 mL of collagenase solution per mouse, depending on tissue mass.</li>
	<li>Prepare collagenase solution for human breast tissue: Sterile filter 18 mL of RPMI-1640, 200 &#181;L of 100x penicillin-streptomycin solution (pen/strep), 200 &#181;L of 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) Buffer, 1 mL of FBS, and 400 &#181;L of 0.1 g/mL Collagenase A using a 50 mL/0.2 &#181;m filter flask. Allocate between 10 mL and 20 mL per tissue sample, depending on the tissue mass.</li>
</ol>
3. Preparing media
<ol>
	<li>Prepare organoid media: Sterile filter basal cell medium with 1% pen/strep, and 1% Insulin-Transferrin-Selenium (ITS) using a 50 mL/0.2 &#181;m filter flask. To make organoid growth factor media, add basic fibroblast growth factor (bFGF) to a final concentration of 2.5 nM.</li>
	<li>Prepare mammary epithelial media: To make 100 mL of mammary epithelial media, sterile filter high-glucose common basal medium with 1 mL of 100x glutamine supplement, 1 mL of pen/strep, 1 mL of 10 mM HEPES buffer (7.3 pH), 250 &#181;L of 30% BSA stock, 1 &#181;L of 1 mg/mL cholera toxin stock, 1 mL of 50 &#181;g/mL hydrocortisone stock in PBS, 50 &#181;L of 10 mg/mL human insulin solution, 10 &#181;L of 50 &#181;g/mL epidermal growth factor (EGF) stock, and 1% FBS using a 150 mL/0.2 &#181;m filter flask. Store the media at 4 &#176;C and use for up to 2 weeks.</li>
	<li>Prepare amphotericin wash: Sterile filter PBS with 2% pen/strep and 2% amphotericin B. Store at 4 &#176;C.</li>
</ol>
4. Collecting and digesting tissue
<ol>
	<li>Mouse mammary tissue
	<ol>
		<li>Euthanize the mouse by placing in a CO2 chamber for 2-5 min, and then follow with cervical dislocation. With the ventral side facing upward, splay mouse limbs and use four 19 G needles to pin the mouse by the paws to a board covered with an absorbent pad. Spray with 70% ethanol to smooth the fur down and sanitize the skin. Wipe away feces with a gauze pad or tissue.</li>
		<li>Starting just above the anogenital region, cut upward from the midline using surgical scissors, taking care not to pierce through the peritoneum. Upon reaching the chin, make lateral cuts down both clavicles and down hind legs, and pin the skin of the mouse taut to the board to expose mammary fat pads.</li>
		<li>Locate the inguinal mammary fat pads on wild-type mice by identifying the inguinal lymph node located near the hindlimbs. Locate the thoracic mammary fat pads on wild-type mice as the thicker, vascularized tissue beneath the front limbs.</li>
		<li>Use forceps to elevate the mammary fat pad. Avoid collecting underlying muscle. Using the blunt end of sharp-blunt scissors, create a pocket underneath the mammary fat pad, away from the skin. Cut away the mammary fat pad in one complete piece.</li>
		<li>Once mammary fat pads have been removed, rinse in PBS before placing them in a sterile tissue culture dish. Quickly transfer to a tissue culture hood. 
		NOTE: For mammary tumors, use a cotton swab wetted with PBS to gently roll the tumor away from the skin. Be certain to avoid darkened or soft areas, as dark discoloration indicates necrosis, which will not yield healthy organoids.</li>
		<li>Mince the mammary tumors with a #10 or #11 scalpel to loosen tissue until it reaches a paste-like consistency. Transfer the minced tissue into a conical tube containing 10-30 mL of collagenase solution using a scalpel. To ensure all tissue is collected, pipette 1 mL of collagenase solution onto the tissue culture plate and back into the conical tube. 
		NOTE: To produce larger organoids, mechanical digestion should be minimized, leaving some small visible pieces of tissue intact. Alternatively, tissue can be stored frozen for later organoid preparation with minimal loss in viability. To do so, wash tissue in a solution of PBS or basal cell media + 1% FBS, and then coarsely mince to increase surface area (keeping the tissue in one or two solid pieces). Move the tissue to a cryo-vial, top with freezing media (90% FBS + 10% dimethyl sulfoxide (DMSO)). Freeze the vials in a controlled-rate freezing container overnight before moving to storage in liquid nitrogen.</li>
		<li>Place the conical tube into a 37 &#176;C benchtop shaking incubator at 180 RPM until the tissue becomes stringy and the collagenase solution becomes cloudy. For example, a large tissue mass (around 500-800 mg) from a tumor takes 30-60 min. A smaller tissue mass (around 100-300 mg) from wild-type mammary fat pads takes about 20-30 min. If uncertain, check at 5 min intervals.</li>
		<li>After incubation, centrifuge the conical tube for 10 min at 550 x g at room temperature (RT).</li>
		<li>Carefully aspirate the supernatant from the conical tube. 
		NOTE: Moving forward, pre-coat all pipette tips, serological pipets, and conical tubes with BSA solution to avoid loss of organoids due to adhesion to plastic.</li>
		<li>Add 8 mL of basal cell media and 80 &#181;L of DNase solution [2 U/&#181;L] to the tube. Invert gently for 1-3 min.</li>
		<li>Add 12 mL of basal cell media to the tube and carefully mix by pipetting or gently rotate the tube 15 times to mix.</li>
		<li>Centrifuge for 10 min at 550 x g at RT.</li>
		<li>Aspirate the supernatant, and then resuspend the pellet in 12 mL of basal cell media.</li>
		<li>Let the heaviest tissue fragments settle to the bottom. Collect the supernatant with a serological pipet and transfer to a 15 mL conical tube. This suspension contains epithelial organoids and stromal/immune cells.</li>
	</ol>
	</li>
	<li>Human breast tissue
	<ol>
		<li>Process the human breast tissue samples for organoids or store them within 24 h of collection. Store the samples at 4 &#176;C in CO2-Independent media with 1% 100x antibiotic-antimycotic.</li>
		<li>Transfer the tissue into a tissue culture plate. Tilt the plate and aspirate the excess storage media, and then rinse the tissue with 5 mL of the amphotericin B wash. Remove the amphotericin B wash immediately.</li>
		<li>Mince the tissue sample with a #10 or #11 scalpel to loosen the tissue until it reaches a paste-like consistency. Transfer the minced tissue into a conical tube containing 10-30 mL of collagenase solution using a scalpel. To ensure all tissue is collected, pipette 1 mL of collagenase solution onto the tissue culture plate and return to the conical tube. 
		NOTE: To produce larger organoids, mechanical digestion should be minimized, leaving some small visible pieces of tissue intact. Starting tissue mass for this protocol ranged between 100-250 mg. Alternatively, tissue can be stored frozen for later organoid preparation with minimal loss in viability after step 4.2.2 in 90% FBS + 10% DMSO as above.</li>
		<li>Place the conical tube into a 37 &#176;C benchtop shaking incubator at 180 RPM until the tissue becomes smaller and collagenase becomes cloudy. Check the tissue at 5 min intervals. Collagenase dissociation of human samples takes roughly 5-20 min.</li>
		<li>After incubation, spin down the conical tube for 10 min at 550 x g at RT.</li>
		<li>Carefully aspirate the supernatant from the conical tube. 
		NOTE: Moving forward, pre-coat all the pipette tips, serological pipets, and conical tubes with BSA solution to avoid loss of organoids due to adhesion to plastic.</li>
		<li>Add 4 mL of basal cell media and 40 &#181;L of DNase solution [2 U/&#181;L] to the conical tube. Invert gently for 3 min.</li>
		<li>Add 6 mL of basal cell media to the tube and carefully mix by pipetting or gently rotate the conical tube 15 times to mix.</li>
		<li>Centrifuge for 10 min at 550 x g at RT.</li>
		<li>Aspirate the supernatant, and then resuspend the pellet in 10 mL of basal cell media.</li>
		<li>Let the heaviest tissue fragments settle to the bottom. Collect the supernatant and transfer it to a 15 mL conical tube. This suspension contains epithelial organoids and stromal/immune cells.</li>
	</ol>
	</li>
</ol>
5. Differential centrifugation
<ol>
	<li>Pulse to 550 x g for 3-4 s at RT, aspirate the supernatant, and resuspend the pellet in 10 mL of basal cell media. Repeat this step three more times (a total of four spins).</li>
	<li>After each centrifugation, ensure that the pellet becomes increasingly opaque. This remaining pellet will be epithelial organoids.</li>
</ol>
6. Collecting small organoids
<ol>
	<li>Pulse to 80-100 x g for 3 s at RT. Collect the supernatant into a fresh BSA-coated tube, and then pulse to 550 x g for 3 s at RT to pellet the small organoids.</li>
</ol>
7. Embedding organoids in BECM
<ol>
	<li>Aliquot appropriate suspension of organoids into microcentrifuge tubes according to the organoid density relative to the amount of BECM per well (Table 1). For example, use 50-100 organoids for 20 &#181;L of BECM in one well of a 96-well plate. 
	NOTE: Organoid density can be counted using the following formula: ((Average number of organoids)/50 &#181;L) x dilution factor.</li>
	<li>Perform all the steps on ice. Place the thawed BECM on ice in a tissue culture hood. While preparing the hood, place all the pipette tips on ice to cool.</li>
	<li>Centrifuge the microcentrifuge tubes for 10 min at 300 x g at RT. Discard the supernatant from the tubes. Move the tubes with organoid pellets to ice and add the appropriate volume of BECM to each microcentrifuge tube (Table 1). 
	NOTE: Since BECM is viscous, add in additional volumes (approximately 10%-20% extra of dome volume) of BECM to account for the loss in the pipet tip.</li>
	<li>Gently pipette up and down to resuspend the organoids in BECM, taking care not to produce bubbles.</li>
	<li>Slowly and carefully pipette the BECM-suspended organoids onto the plating surface. While pipetting, slowly bring up the pipette to create a dome. Fill all the empty wells with PBS to maintain humidity.</li>
	<li>Place the plate into a 37 &#176;C incubator for 1 h to allow BECM to solidify, and then cover with the appropriate volume of media (Table 1).</li>
</ol>
8. Embedding organoids in collagen
<ol>
	<li>Perform all the steps on ice. Prepare the collagen solution by combining, in sequential order, 375 &#181;L of 10x DMEM, 100 &#181;L of 1 N sodium hydroxide (NaOH), and 3 mL of rat tail collagen I solution in a 15 mL conical tube. Pipette mix, taking care not to make bubbles. Titrate the solution to a pH of 7.2-7.4 with small amounts (increments of 1-3 &#181;L) of NaOH or 10x DMEM as needed.</li>
	<li>Coat the bottom of the wells with the minimum amount of collagen required to fully cover the bottom of the well. One approach is to place a small amount of collagen and rock the plate from side to side to coat. Allow the collagen underlays to set at 37 &#176;C for 30 min-2 h.</li>
	<li>Aliquot the appropriate suspension of organoids into microcentrifuge tubes according to the organoid density relative to the amount of collagen per well (Table 1). Place in a 37 &#176;C incubator.</li>
	<li>Store the collagen solution at 4 &#176;C and monitor polymerization by checking for fiber formation under a microscope every 10 min. Collagen will reach appropriate polymerization between 30 min-2 h. 
	NOTE: Proper polymerization can be determined by the presence of fibers branching throughout the matrix. Proceed to step 8.5 immediately once a few fibers are observed in the field of view.</li>
	<li>Centrifuge the microcentrifuge tubes at 300 x g for 10 min&#160;at RT. Discard the supernatant from the tubes. Move the organoid pellets to ice and add the appropriate volume of collagen to each microcentrifuge tube (Table 1). 
	NOTE: Since collagen is viscous, add in additional volumes (approximately 10%-20% extra of dome volume) of collagen to account for the loss in the pipet tip.</li>
	<li>Gently pipette up and down to resuspend organoids in collagen, taking care not to produce bubbles.</li>
	<li>Slowly and carefully pipette the collagen-suspended organoids onto the plating surface. While pipetting, slowly bring up the pipette to create a dome. Fill all the empty wells with PBS to maintain humidity.</li>
	<li>Place the plate into a 37 &#176;C incubator for 1 h to allow collagen to solidify, and then cover with the appropriate volume of media (Table 1).</li>
	<li>NOTE : Organoids maintain viability in 3D matrix for up to 7 days. If imaging is being used for analysis, proceed to steps 9 and 10.</li>
</ol>
9. Fixing embedded organoids
<ol>
	<li>Use a pipette to remove all media from the wells without making contact with ECM domes.</li>
	<li>Fix with 4% paraformaldehyde (PFA)/PBS solution for 5 min.</li>
	<li>Wash two to three times by applying PBS to wells after placing them on a slowly moving shaker. After washes, apply fresh PBS to the domes and store the plate at 4 &#176;C.</li>
</ol>
10. Immunofluorescent staining of embedded organoids
<ol>
	<li>Preparing solutions for immunofluorescent staining
	<ol>
		<li>Permeabilization buffer: Prepare a PBS solution with 10% Triton X-100.</li>
		<li>Blocking buffer: Prepare a PBS solution with 10% FBS and 0.2% Triton X-100.</li>
		<li>Antibody dilution buffer: Prepare a PBS solution with 2% FBS and 0.2% Triton X-100.</li>
	</ol>
	</li>
	<li>Permeabilization and blocking
	<ol>
		<li>Pipette enough permeabilization buffer to cover the ECM domes. Incubate for 1 h at RT on a slowly moving shaker.</li>
		<li>Remove the permeabilization buffer with a pipette and apply the same volume of blocking buffer for 3 h.</li>
	</ol>
	</li>
	<li>Primary antibody incubation
	<ol>
		<li>Remove the blocking buffer with a pipette and apply the antibody dilution buffer containing the primary antibody at manufacturer-specified concentrations. Incubate the sample at 4 &#176;C for 12-16 h on a slowly-moving shaker.</li>
		<li>Remove the primary antibody solution and wash the samples three times for 10 min with PBS at RT on a slowly moving shaker.</li>
	</ol>
	</li>
	<li>Secondary antibody incubation and nuclear stain
	<ol>
		<li>Aspirate the remaining PBS wash and apply the antibody dilution buffer containing secondary antibody at manufacturer-specified concentrations. Additionally, add DAPI or Hoechst (to label nuclei) or phalloidin (to label actin) to the buffer at a 1:250 ratio. Incubate for 2-4 h at RT on a slowly-moving shaker.</li>
		<li>Remove the secondary antibody solution and wash samples three times for 10 min in PBS at RT on a shaker. Store the samples in PBS at 4 &#176;C until imaging.</li>
	</ol>
	</li>
</ol>

<ol><li>Ghandi, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Next-generation+characterization+of+the+cancer+cell+line+encyclopedia%5BTitle%5D)+AND+%22Nature%22%5BJournal%5D)">Next-generation characterization of the cancer cell line encyclopedia.</a> Nature. 569 (7757), 503-508 (2019).</li>
<li>Roarty, K., Echeverria, G. V. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Laboratory+models+for+investigating+breast+cancer+therapy+resistance+and+metastasis%5BTitle%5D)+AND+%22Frontiers+in+Oncology%22%5BJournal%5D)">Laboratory models for investigating breast cancer therapy resistance and metastasis.</a> Frontiers in Oncology. 11, 645698(2021).</li>
<li>Hanahan, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Hallmarks+of+cancer%3A+New+dimensions%5BTitle%5D)+AND+%22Cancer+Discovery%22%5BJournal%5D)">Hallmarks of cancer: New dimensions.</a> Cancer Discovery. 12 (1), 31-46 (2022).</li>
<li>Gillet, J. P., Varma, S., Gottesman, M. M. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+clinical+relevance+of+cancer+cell+lines%5BTitle%5D)+AND+%22Journal+of+the+National+Cancer+Institute%22%5BJournal%5D)">The clinical relevance of cancer cell lines.</a> Journal of the National Cancer Institute. 105 (7), 452-458 (2013).</li>
<li>Lambert, A. W., Pattabiraman, D. R., Weinberg, R. A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Emerging+biological+principles+of+metastasis%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Emerging biological principles of metastasis.</a> Cell. 168 (4), 670-691 (2017).</li>
<li>Lo, Y. H., Karlsson, K., Kuo, C. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Applications+of+organoids+for+cancer+biology+and+precision+medicine%5BTitle%5D)+AND+%22Nature+Cancer%22%5BJournal%5D)">Applications of organoids for cancer biology and precision medicine.</a> Nature Cancer. 1 (8), 761-773 (2020).</li>
<li>Drost, J., Clevers, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organoids+in+cancer+research%5BTitle%5D)+AND+%22Nature+Reviews+Cancer%22%5BJournal%5D)">Organoids in cancer research.</a> Nature Reviews Cancer. 18 (7), 407-418 (2018).</li>
<li>Tuveson, D., Clevers, H. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+modeling+meets+human+organoid+technology%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Cancer modeling meets human organoid technology.</a> Science. 364 (6444), 952-955 (2019).</li>
<li>Fujii, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+colorectal+tumor+organoid+library+demonstrates+progressive+loss+of+niche+factor+requirements+during+tumorigenesis%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">A colorectal tumor organoid library demonstrates progressive loss of niche factor requirements during tumorigenesis.</a> Cell Stem Cell. 18 (6), 827-838 (2016).</li>
<li>van de Wetering, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Prospective+derivation+of+a+living+organoid+biobank+of+colorectal+cancer+patients%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Prospective derivation of a living organoid biobank of colorectal cancer patients.</a> Cell. 161 (4), 933-945 (2015).</li>
<li>Boj, S. F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organoid+models+of+human+and+mouse+ductal+pancreatic+cancer%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Organoid models of human and mouse ductal pancreatic cancer.</a> Cell. 160 (1-2), 324-338 (2015).</li>
<li>Sachs, N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+living+biobank+of+breast+cancer+organoids+captures+disease+heterogeneity%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">A living biobank of breast cancer organoids captures disease heterogeneity.</a> Cell. 172 (1-2), 373-386 (2018).</li>
<li>Broutier, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Human+primary+liver+cancer-derived+organoid+cultures+for+disease+modeling+and+drug+screening%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">Human primary liver cancer-derived organoid cultures for disease modeling and drug screening.</a> Nature Medicine. 23 (12), 1424-1435 (2017).</li>
<li>Kim, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+lung+cancer+organoids+as+in+vitro+cancer+models+for+therapeutic+screening%5BTitle%5D)+AND+%22Nature+Communications%22%5BJournal%5D)">Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening.</a> Nature Communications. 10 (1), 3991(2019).</li>
<li>Jacob, F., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+patient-derived+glioblastoma+organoid+model+and+biobank+recapitulates+inter-+and+intra-tumoral+heterogeneity%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">A patient-derived glioblastoma organoid model and biobank recapitulates inter- and intra-tumoral heterogeneity.</a> Cell. 180 (1), 188-204 (2020).</li>
<li>Yan, H. H. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+comprehensive+human+gastric+cancer+organoid+biobank+captures+tumor+subtype+heterogeneity+and+enables+therapeutic+screening%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">A comprehensive human gastric cancer organoid biobank captures tumor subtype heterogeneity and enables therapeutic screening.</a> Cell Stem Cell. 23 (6), 882-897 (2018).</li>
<li>Njoroge, R. N., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organoids+model+distinct+vitamin+E+effects+at+different+stages+of+prostate+cancer+evolution%5BTitle%5D)+AND+%22Scientific+Reports%22%5BJournal%5D)">Organoids model distinct vitamin E effects at different stages of prostate cancer evolution.</a> Scientific Reports. 7 (1), 16285(2017).</li>
<li>Lee, S. H., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tumor+evolution+and+drug+response+in+patient-derived+organoid+models+of+bladder+cancer%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Tumor evolution and drug response in patient-derived organoid models of bladder cancer.</a> Cell. 173 (2), 515-528 (2018).</li>
<li>Cheung, K. J., Gabrielson, E., Werb, Z., Ewald, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Collective+invasion+in+breast+cancer+requires+a+conserved+basal+epithelial+program%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Collective invasion in breast cancer requires a conserved basal epithelial program.</a> Cell. 155 (7), 1639-1651 (2013).</li>
<li>Wrenn, E. D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Regulation+of+collective+metastasis+by+nanolumenal+signaling%5BTitle%5D)+AND+%22Cell%22%5BJournal%5D)">Regulation of collective metastasis by nanolumenal signaling.</a> Cell. 183 (2), 395-410 (2020).</li>
<li>Kopper, O., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((An+organoid+platform+for+ovarian+cancer+captures+intra-+and+interpatient+heterogeneity%5BTitle%5D)+AND+%22Nature+Medicine%22%5BJournal%5D)">An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity.</a> Nature Medicine. 25 (5), 838-849 (2019).</li>
<li>Vlachogiannis, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+organoids+model+treatment+response+of+metastatic+gastrointestinal+cancers%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.</a> Science. 359 (6378), 920-926 (2018).</li>
<li>Yao, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+organoids+predict+chemoradiation+responses+of+locally+advanced+rectal+cancer%5BTitle%5D)+AND+%22Cell+Stem+Cell%22%5BJournal%5D)">Patient-derived organoids predict chemoradiation responses of locally advanced rectal cancer.</a> Cell Stem Cell. 26 (1), 17-26 (2020).</li>
<li>Yao, J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((A+pancreas+tumor+derived+organoid+study%3A+from+drug+screen+to+precision+medicine%5BTitle%5D)+AND+%22Cancer+Cell+International%22%5BJournal%5D)">A pancreas tumor derived organoid study: from drug screen to precision medicine.</a> Cancer Cell International. 21 (1), 398(2021).</li>
<li>Vlachogiannis, G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Patient-derived+organoids+model+treatment+response+of+metastatic+gastrointestinal+cancers%5BTitle%5D)+AND+%22Science%22%5BJournal%5D)">Patient-derived organoids model treatment response of metastatic gastrointestinal cancers.</a> Science. 359 (6378), 920-926 (2018).</li>
<li>Chan, I. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Cancer+cells+educate+natural+killer+cells+to+a+metastasis-promoting+cell+state%5BTitle%5D)+AND+%22Journal+of+Cell+Biology%22%5BJournal%5D)">Cancer cells educate natural killer cells to a metastasis-promoting cell state.</a> Journal of Cell Biology. 219 (9), 202001134(2020).</li>
<li>Chan, I. S., Ewald, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organoid+co-culture+methods+to+capture+cancer+cell-natural+killer+cell+interactions%5BTitle%5D)+AND+%22Methods+in+Molecular+Biology%22%5BJournal%5D)">Organoid co-culture methods to capture cancer cell-natural killer cell interactions.</a> Methods in Molecular Biology. 2463, 235-250 (2022).</li>
<li>Chan, I. S., Ewald, A. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((The+changing+role+of+natural+killer+cells+in+cancer+metastasis%5BTitle%5D)+AND+%22The+Journal+of+Clinical+Investigation%22%5BJournal%5D)">The changing role of natural killer cells in cancer metastasis.</a> The Journal of Clinical Investigation. 132 (6), 143762(2022).</li>
<li>Guy, C. T., Cardiff, R. D., Muller, W. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Induction+of+mammary+tumors+by+expression+of+polyomavirus+middle+T+oncogene%3A+a+transgenic+mouse+model+for+metastatic+disease%5BTitle%5D)+AND+%22Molecular+and+Cellular+Biology%22%5BJournal%5D)">Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease.</a> Molecular and Cellular Biology. 12 (3), 954-961 (1992).</li>
<li>Feldman, A. T., Wolfe, D. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Tissue+processing+and+hematoxylin+and+eosin+staining%5BTitle%5D)+AND+%22Methods+in+Molecular+Biology%22%5BJournal%5D)">Tissue processing and hematoxylin and eosin staining.</a> Methods in Molecular Biology. 1180, 31-43 (2014).</li>
<li>LeSavage, B. L., Suhar, R. A., Broguiere, N., Lutolf, M. P., Heilshorn, S. C. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Next-generation+cancer+organoids%5BTitle%5D)+AND+%22Nature+Materials%22%5BJournal%5D)">Next-generation cancer organoids.</a> Nature Materials. 21 (2), 143-159 (2022).</li>
<li>Nguyen-Ngoc, K. V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((3D+culture+assays+of+murine+mammary+branching+morphogenesis+and+epithelial+invasion%5BTitle%5D)+AND+%22Methods+in+Molecular+Biology%22%5BJournal%5D)">3D culture assays of murine mammary branching morphogenesis and epithelial invasion.</a> Methods in Molecular Biology. 1189, 135-162 (2015).</li>
<li>Padmanaban, V., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Organotypic+culture+assays+for+murine+and+human+primary+and+metastatic-site+tumors%5BTitle%5D)+AND+%22Nature+Protocols%22%5BJournal%5D)">Organotypic culture assays for murine and human primary and metastatic-site tumors.</a> Nature Protocols. 15 (8), 2413-2442 (2020).</li>
</ol>

The authors declare no conflicts of interest.

Different methods have been described in the literature to generate tumor organoids. This protocol highlights a method for generating tumor organoids directly from the tumor without passaging. Using this method, tumor organoids are producible within hours of initiating the procedure and generate close to 100% viable organoids compared to 70% reported in the literature31. In comparison, other methods require serial passaging of cells into organoids over several weeks. Thus, the downstream applicati...

The ability to model epithelial cells in vitro has been the foundation of modern biomedical research because it captures cellular features that are not accessible in vivo. For instance, growing epithelial cell lines in a two-dimensional plane can provide an assessment of the molecular changes that occur in an epithelial cell during proliferation1. Furthermore, measuring the dynamic regulation between signaling and gene expression is limited in in vivo systems2. In cancer research, cancer epithelial cell line modeling has enabled the identification of molecular drivers of disease progression and potential drug targets3. However, growing cancer epithelial cell lines on a two-dimensional plane has limitations, as most are genetically immortalized and modified, often clonal in nature, selected for their ability to grow in non-physiologic conditions, limited in their assessment of three-dimensional (3D) tumor tissue architecture, and do not adequately model microenvironment interactions within a realistic tissue environment4. These constraints are particularly evident in modeling metastasis, which in vivo includes several distinct biological stages, including invasion, dissemination, circulation, and colonization at the distant organ site5.
Cancer epithelial organoids have been developed to better recapitulate the 3D environment and behavior of tumors6,7,8. Organoids were first developed from single LRG5+ intestinal crypt cells and differentiated to represent the 3D structure of crypt-villus units that maintained the hierarchical structure of the small intestine in vitro9. This approach permitted real-time visualization and characterization of self-organizing tissue architecture under homeostatic and stress conditions. As a natural extension, cancer epithelial organoids were developed to model many different cancer types, including colorectal10, pancreatic11, breast12, liver13, lung14, brain15, and gastric cancers16. Cancer epithelial organoids have been exploited to characterize cancer evolution17,18 and metastatic spatiotemporal behaviors19,20 and interrogate tumor heterogeneity21, and test chemotherapies22. Cancer epithelial organoids have also been isolated and collected during ongoing clinical trials to predict patient response to anticancer agents and radiation therapy ex vivo8,23,24,25. Furthermore, systems incorporating cancer epithelial organoids can be combined with other non-cancer cells, such as immune cells, to form a more comprehensive model of the tumor microenvironment to visualize interactions in real-time, uncover how cancer epithelial cells change the fundamental nature of cytotoxic effector immune cells such as natural killer cells, and test potential immunotherapies and antibody-drug dependent cytotoxic activity26,27,28. This article demonstrates a method of generating epithelial organoids without passaging and embedding in collagen and basement extracellular matrix (ECM). Additionally, techniques for downstream imaging of isolated organoids are also shared.

<table><tbody><tr><td>10 mM HEPES Buffer</td><td>Gibco&amp;nbsp;</td><td>15630080</td><td></td></tr><tr><td>100x Antibiotic-Antimycotic&amp;nbsp;</td><td>Gibco&amp;nbsp;</td><td>15240-096</td><td></td></tr><tr><td>100x Glutamax</td><td>Life Technologies&amp;nbsp;</td><td>35050-061</td><td>Glutamine supplement</td></tr><tr><td>100x Insulin-Transferrin-Selenium (ITS)&amp;nbsp;</td><td>Life Technologies&amp;nbsp;</td><td>51500-056</td><td></td></tr><tr><td>100x Penicillin/Streptomycin (Pen/Strep)</td><td>Sigma&amp;nbsp;</td><td>P4333</td><td></td></tr><tr><td>10x DMEM</td><td>Sigma&amp;nbsp;</td><td>D2429</td><td></td></tr><tr><td>50 mL/0.2 &amp;micro;m filter flask</td><td>Fisher&amp;nbsp;</td><td>#564-0020</td><td></td></tr><tr><td>Amphotericin B</td><td>Life Technologies&amp;nbsp;</td><td>15290-018</td><td></td></tr><tr><td>bFGF</td><td>Sigma</td><td>F0291</td><td></td></tr><tr><td>BSA Solution (32%)</td><td>Sigma&amp;nbsp;</td><td>#A9576</td><td></td></tr><tr><td>Cholera Toxin&amp;nbsp;</td><td>Sigma&amp;nbsp;</td><td>C8052</td><td></td></tr><tr><td>CO&lt;sub&gt;2&lt;/sub&gt;-Independent Medium&amp;nbsp;</td><td>Gibco</td><td>18045-088</td><td></td></tr><tr><td>Collagenase A&amp;nbsp;</td><td>Sigma&amp;nbsp;</td><td>C2139</td><td></td></tr><tr><td>Deoxyribonuclease I from bovine pancreas (DNase)</td><td>Sigma</td><td>D4263</td><td></td></tr><tr><td>DMEM with 4500 mg/L glucose, sodium pyruvate, and sodium bicarbonate, without L-glutamine, liquid, sterile-filtered, suitable for cell culture</td><td>Sigma</td><td>D6546</td><td>Common basal medium</td></tr><tr><td>D-MEM/F12&amp;nbsp;</td><td>Life Technologies&amp;nbsp;</td><td>#10565-018</td><td>Basal cell medium</td></tr><tr><td>Dulbecco&#039;s Phosphate Buffered Saline (D-PBS)&amp;nbsp;</td><td>Sigma</td><td>#D8662</td><td>PBS</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Sigma&amp;nbsp;</td><td>#F0926</td><td></td></tr><tr><td>Gentamicin&amp;nbsp;</td><td>Life Technologies&amp;nbsp;</td><td>#15750-060</td><td></td></tr><tr><td>Human epidermal growth factor (EGF)</td><td>Sigma&amp;nbsp;</td><td>E9644</td><td></td></tr><tr><td>Hydrocortisone&amp;nbsp;</td><td>Sigma&amp;nbsp;</td><td>H0396</td><td></td></tr><tr><td>Insulin&amp;nbsp;</td><td>Sigma&amp;nbsp;</td><td>#I9278</td><td></td></tr><tr><td>Matrigel&amp;nbsp;</td><td>Corning&amp;nbsp;</td><td>#354230</td><td>Basement Extracellular Matrix (BECM)</td></tr><tr><td>NaOH (1 N)</td><td>Sigma&amp;nbsp;</td><td>S2770</td><td></td></tr><tr><td>Rat Tail Collagen I</td><td>Corning&amp;nbsp;</td><td>354236</td><td></td></tr><tr><td>RPMI-1640 media</td><td>Fisher&amp;nbsp;</td><td>SH3002701</td><td></td></tr><tr><td>Trypsin&amp;nbsp;</td><td>Life Technologies&amp;nbsp;</td><td>27250-018</td><td></td></tr></tbody></table>

generating and imaging mouse and human epithelial organoids from normal and tumor mammary tissue without passaging

Generating and Imaging Mouse and Human Epithelial Organoids from Normal and Tumor Mammary Tissue Without Passaging

Organoids are a reliable method for modeling organ tissue due to their self-organizing properties and retention of function and architecture after propagation from primary tissue or stem cells. This method of organoid generation forgoes single-cell differentiation through multiple passages and instead uses differential centrifugation to isolate mammary epithelial organoids from mechanically and enzymatically dissociated tissues. This protocol provides a streamlined technique for rapidly producing small and large epithelial organoids from both mouse and human mammary tissue in addition to techniques for organoid embedding in collagen and basement extracellular matrix. Furthermore, instructions for in-gel fixation and immunofluorescent staining are provided for the purpose of visualizing organoid morphology and density. These methodologies are suitable for myriad downstream analyses, such as co-culturing with immune cells and ex vivo metastasis modeling via collagen invasion assay. These analyses serve to better elucidate cell-cell behavior and create a more complete understanding of interactions within the tumor microenvironment.

The images featured in Figure 1 provide an example of wild-type and tumorous mammary epithelial organoids from human and mouse tissues. An at-a-glance illustration of the method for isolating epithelial organoids through differential centrifugation is provided in the cartoon workflow in Figure 1A, showing that primary tissues from different species can be processed in near-identical ways while yielding epithelial tissue as shown in the brightfield images (<stron...

This protocol discusses an approach for generating epithelial organoids from primary normal and tumor mammary tissue through differential centrifugation. Furthermore, instructions are included for three-dimensional culturing as well as immunofluorescent imaging of embedded organoids.

Organoids are a reliable method for modeling organ tissue due to their self-organizing properties and retention of function and architecture after ...

generating-imaging-mouse-human-epithelial-organoids-from-normal-tumor

Research

JoVE Journal

Cancer Research

Time-lapse imaging is used to assess behavior of primary preneoplastic mammary epithelial cells derived from genetically engineered mouse models of breast cancer risk to determine if there are correlations between specific behavioral parameters and distinct genetic lesions.

Time-lapse Imaging of Primary Preneoplastic Mammary Epithelial Cells Derived from Genetically Engineered Mouse Models of Breast Cancer

Primary cell culture using intact tissue organoids provides a model system that mimics the multi-cellular in vivo microenvironment. We developed a serum-free primary breast epithelium tissue culture model that perpetuates mixed cell culture lineages and exhibits differentiated morphology, without enzymatic tissue disruption. Breast organoids remain viable for &gt;6 months.

Non-enzymatic, Serum-free Tissue Culture of Pre-invasive Breast Lesions for Spontaneous Generation of Mammospheres

Organoids developed from mouse mammary glands were irradiated and characterized to assess epithelial traits and interactions with immune cells. Irradiated organoids can be used to better evaluate cell-cell interactions that may lead to tumor cell recruitment in irradiated normal tissue.

Growth and Characterization of Irradiated Organoids from Mammary Glands

We show a method for necropsy and dissection of mouse prostate cancer models, focusing on prostate tumor dissection. A step-by-step protocol for generation of mouse prostate tumor organoids is also presented.

Generation of Tumor Organoids from Genetically Engineered Mouse Models of Prostate Cancer

A protocol to generate human primary endometrial organoids that consist of epithelial and stromal cells and retain characteristics of the native endometrial tissue is presented. This protocol describes methods from uterine tissue acquisition to the histologic processing of endometrial organoids.

Generation of Multicellular Human Primary Endometrial Organoids

The mammary gland is a bilayered structure, comprising outer myoepithelial and inner luminal epithelial cells. Presented is a protocol to prepare organoids using differential trypsinization. This efficient method allows researchers to separately manipulate these two cell types to explore questions concerning their roles in mammary gland form and function.

Generation of Mosaic Mammary Organoids by Differential Trypsinization

This protocol describes methodologies to establish mouse endometrial epithelial organoids for gene expression and histological analyses.

Establishing 3D Endometrial Organoids from the Mouse Uterus

A detailed protocol is provided here for establishing human breast organoids from patient-derived breast tumor resections or normal breast tissue. The protocol provides comprehensive step-by-step instructions for culturing, freezing, and thawing human patient-derived breast organoids.

Establishment and Culture of Patient-Derived Breast Organoids

This protocol describes a defined hydrogel-based method to generate human breast organoids that recapitulate key features of mammary morphogenesis in a controlled three-dimensional culture system.

A Defined Hydrogel-Based Method For Generating Three-Dimensional Human Breast Organoids That Recapitulate Mammary Morphogenesis

We describe a protocol for preclinical in vivo tracking of cancer metastasis. It is based on a radionuclide-fluorescence reporter combining the sodium iodide symporter, detected by non-invasive [18F]tetrafluoroborate-PET, and a fluorescent protein for streamlined ex vivo confirmation. The method is applicable for preclinical in vivo cell tracking beyond tumor biology.

Radionuclide-fluorescence Reporter Gene Imaging to Track Tumor Progression in Rodent Tumor Models

Learn to generate epithelial organoids from normal and tumor mammary tissue without passaging using differential centrifugation. This method enables 3D culture and immunofluorescent imaging for cancer research.

Generating and Imaging Mouse and Human Epithelial Organoids from Normal and Tumor Mammary Tissue Without Passaging

Explore More Videos